Pyroptosis in Kidney Disease

被引:38
|
作者
Wang, Yujia [1 ]
Li, Yinshuang [1 ]
Xu, Yanfang [1 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Blood Purificat Res Ctr, Dept Nephrol, Fuzhou 350005, Peoples R China
基金
中国国家自然科学基金;
关键词
Pyroptosis; Kidney disease; ENDOPLASMIC-RETICULUM STRESS; NONCANONICAL INFLAMMASOME ACTIVATION; PROGRAMMED CELL-DEATH; TOLL-LIKE RECEPTOR; NLRP3; INFLAMMASOME; GASDERMIN D; DIABETIC-NEPHROPATHY; OXIDATIVE STRESS; BAY; 11-7082; MOLECULAR-MECHANISMS;
D O I
10.1016/j.jmb.2021.167290
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the last several decades, apoptosis interference has been considered clinically irrelevant in the context of renal injury. Recent discovery of programmed necrotic cell death, including necroptosis, ferroptosis, and pyroptosis refreshed our understanding of the role of cell death in kidney disease. Pyroptosis is characterized by a lytic pro- inflammatory type of cell death resulting from gasdermin-induced membrane permeabilization via activation of inflammatory caspases and inflammasomes. The danger-associated molecular patterns (DAMPs), alarmins and pro-inflammatory cytokines are released from pyroptotic cells in an uncontrolled manner, which provoke inflammation, resulting in secondary organ or tissue injuries. The caspases and inflammasome activation-related proteins and pore-forming effector proteins known as GSDMD and GSDME have been implicated in a variety of acute and chronic microbial and non-microbial kidney diseases. Here, we review the recent advances in pathological mechanisms of pyroptosis in kidney disease and highlight the potential therapeutic strategies in future. (c) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Diosgenin inhibited podocyte pyroptosis in diabetic kidney disease by regulating the Nrf2/NLRP3 pathway
    Tang, Yu
    Hu, Wenxiao
    Peng, Yajun
    Ling, Xiangdong
    BIOCELL, 2024, 48 (10)
  • [32] Rutaecarpine protects podocytes in diabetic kidney disease by targeting VEGFR2/NLRP3-mediated pyroptosis
    Hu, Xueru
    Wang, Jingjing
    Jiang, Ling
    Liu, Xueqi
    Ge, Qingmiao
    Wang, Qianhui
    Qi, Xiangming
    Wu, Yonggui
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
  • [33] SGLT2 Inhibitor Attenuates Inflammatory Response in Diabetic Kidney Disease by Inhibiting GSDMD-Related Pyroptosis
    Ren, Shijing
    Xue, Yaoming
    DIABETES, 2020, 69
  • [34] Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease
    Ji, Nan
    Qi, Zhongwen
    Wang, Yueyao
    Yang, Xiaoya
    Yan, Zhipeng
    Li, Meng
    Ge, Qihui
    Zhang, Junping
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 2647 - 2666
  • [35] Pyroptosis and its role in autoimmune skin disease
    Yao, Yuanjun
    Wang, Zehong
    Li, Junqin
    Peng, Aihong
    Cao, Yue
    Liang, Nannan
    Zhang, Kaiming
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (07)
  • [36] Pyroptosis: A New Insight Into Eye Disease Therapy
    Zhang, Yun
    Jiao, Yan
    Li, Xun
    Gao, Sheng
    Zhou, Nenghua
    Duan, Jianan
    Zhang, Meixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Exploring the role of pyroptosis in the pathogenicity of heart disease
    Bhatti, Rohail
    Sato, Priscila Y.
    FRONTIERS IN PHYSIOLOGY, 2024, 15
  • [38] Research progress of the relationship between pyroptosis and disease
    Ma, Yuze
    Jiang, Jiaxuan
    Gao, Yuan
    Shi, Tianshu
    Zhu, Xiaobo
    Zhang, Kaijia
    Lu, Ke
    Xue, Bin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (07): : 2213 - 2219
  • [39] Nanomaterials for Disease Treatment by Modulating the Pyroptosis Pathway
    Wang, Mengzhen
    Fu, Qinrui
    ADVANCED HEALTHCARE MATERIALS, 2024, 13 (01)
  • [40] Pyroptosis in inflammation-related respiratory disease
    Yuanyu Feng
    Min Li
    Xiaoting Yangzhong
    Xifeng Zhang
    Anju Zu
    Yunjiao Hou
    Lin Li
    Shibo Sun
    Journal of Physiology and Biochemistry, 2022, 78 : 721 - 737